Method for predicting treatment response and test for safe use of mesenchymal stem cells on inflammatory diseases
AssigneesFundacióN PúBlica Andaluza Progreso Y Salud, Instituto De Salud Carlos III
InventorsBernat Soria Escoms, Abdelkrim Hmadcha, Lourdes Acosta López, Natalia Escacena Acosta
Life of this patent
Estimating the term…
Abstract
The present invention refers to the use of tissue type plasminogen activator (tPA) and/or plasminogen activator inhibitor (PAI-1) for prognosticating or predicting a thrombotic event associated to the treatment with MSCs of a human subject suffering from an inflammatory disease.
Claims17
(canceled)
A method for prognosticating or predicting a thrombotic event associated to the treatment with MSCs of a human subject suffering from an inflammatory disease, by predicting or prognosticating the response of said human subject to said treatment, wherein said method comprises:
- a. obtaining a sample of isolated MSCs,
- b. contacting the isolated MSCs of step (a) with human blood serum obtained by centrifugation of human blood from the human subject,
- c. using, as an indicator, (1) expression levels of tissue type plasminogen activator (tPA) protein or mRNA encoding tPA in the biological sample obtained from step (b), or (2) expression levels of plasminogen activator inhibitor (PAI-1) protein or mRNA encoding PAI-1 in the biological sample obtained from step (b), or (3) expression levels of tPA protein or mRNA encoding tPA and PAI-1 protein or mRNA encoding PAI-1 in the biological sample obtained from step (b),
- wherein the result is indicative of a positive response if the expression levels of protein tPA, or mRNA encoding tPA in said biological sample are increased in comparison to a reference sample and/or a positive control, or if the expression levels of PAI-1 protein or mRNA encoding PAI-1 in said biological sample are decreased in comparison to a reference sample and/or a positive control, or if the expression levels of protein tPA or mRNA encoding tPA in the said biological sample are increased in comparison to a reference sample and/or a positive control and if the expression levels of PAI-1 protein or mRNA encoding PAI-1 in said biological sample are decreased in comparison to a reference sample and/or a positive control.
-8. (canceled)
A kit suitable for prognosticating or predicting a thrombotic event associated to the treatment with MSCs of a human subject suffering from inflammatory disease, comprising at least one oligonucleotide(s) capable of hybridizing with mRNAs of tPA and/or PAI-1.
A kit suitable for prognosticating or predicting a thrombotic event associated to the treatment with MSCs of a human subject suffering from inflammatory disease, which comprises a media having at least a capture antibody capable of complexing with any of biomarker proteins tPA or PAI-1 or a fragment thereof and an assay for the detection of a complex of the biomarker and the capture antibody.
Dependencies are inferred from the claim text.